Becton Dickinson and Co raised its 2026 adjusted profit forecast to $12.72 per share after beating second-quarter earnings estimates on Thursday afternoon. Shares rose 5% as demand for GLP-1 injection pens and surgical equipment offset rising raw material costs. Cost pressures from higher oil and resin prices linked to the Middle East conflict are a key focus for investors tracking the medical supplier's margin sustainability.
Becton Dickinson raises 2026 profit forecast on demand
Becton Dickinson raised its annual profit forecast and beat quarterly estimates as demand for injection pens used for GLP-1 therapies remains high. The medical device maker expects adjusted 2026 earnings between $12.52 and $12.72 per share while appointing Vitor Roque as its permanent CFO.
Xurve View
Insights:
Xurve View



